If you are one of the small and diminishing minority of people who think that the public at large is in love with the patent system and all that it has achieved, this little piece by Harriet A. Washington in the Huffington Post will soon correct that false impression (thanks, Gareth Williams of Marks & Clerk, for the link). Entitled "Gene Patenting Produces Profits, Not Cures", this article paints a picture of the patent system which is one of the following -- and you can decide for yourselves - (a) completely and utterly true; (b) selectively and misleadingly true; (c) true for the United States only; (d) generally false; (e) completely false. Harriet is author of Deadly Monopolies.
Two little gems have just emerged from the Strategic Advisory Board on Intellectual Property Policy, SABIP. They are a 16-page report of the proceedings of a policy panel debate held last February to discuss the issues raised by the proposed Google Books settlement, together with SABIP's own policy recommendations (here) and a 12-page document, "Attitudes and Behaviours of Consumers in the Digital Age Policy Bulletin" (the IPKat thinks that 'Policy Bulletin' isn't actually part of the name of the report, but who is he to challenge the textual integrity of a media release?). You can download it here. This Kat hasn't read either, since they both disagreed violently with his Google Chrome browser which peppered him with error messages. They both seem, from what he can tell, to contain very little text and a lot of empty space and/or artwork. Personally, especially given the need to trim public expenditure and enhance efficiency, he'd have preferred both documents in boring old Word but maybe a few weeks sooner.
Regarding Harriet Washington's article, I'm not sure it's quite justified to infer from anything about the public mood from an anti-capitalist rant by a single author trying to promote her book.
ReplyDeleteI have no doubt that the public at large doesn't love the patent system. But I see little evidence that that hate it either. With the exception of pharma lobbyists, liberal academics and a few journalists, I suggest that most people simply aren't interested one way or the other.